Vanda Pharmaceuticals

FDA rejects Vanda’s jet lag drug following yearslong dispute and ‘long-shot’ review Endpoints NewsVanda Pharmaceuticals (VNDA) Faces FDA Setback…

WASHINGTON, Jan. 8, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received…

This article first appeared on GuruFocus. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped roughly 21% in premarket trading after the U.S.…

FDA requests, and Vanda agrees to, a brief extension (to December 5, 2025) for the expedited re-review of…

FDA rejects Vanda’s jet lag drug following yearslong dispute and 'long-shot' review – Endpoints News